T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies

Meta-analysis: Diabetes Mellitus and Risk for CV Outcomes

T2DM Glucose-Lowering Trials: Intensive Treatment

Meta-analysis of Intensive Glycemic Control in T2DM: Major CV Events

Meta-analysis of Intensive Glycemic Control in T2DM: CV Endpoints

ACCORD Post-hoc Analysis: Effect of Intensive Glycemic Control on IHD

ACCORD Post-hoc Analysis: MI and Coronary Revascularization

ACCORD Post-hoc Analysis: UA and Composite CV Outcomes

Meta-analysis of Intensive Glycemic Control in T2DM: Mortality

Intensive Glycemic Control Legacy Effect on CV Outcomes in T2DM

UKPDS 10-Year Follow-up: Insulin/SU vs Conventional Therapy*

BARI 2D Trial: Study Design

BARI 2D: Insulin Sensitization vs Insulin Provision

Glucose-Lowering Drugs and CV Outcomes

UKPDS 10-Year Follow-up: Metformin vs Conventional Therapy UKPDS 10-Year Follow-up: Metformin vs Conventional Therapy* in Newly Diagnosed T2DM

Glucose-Lowering Drugs and CV Outcomes

ORIGIN: Study Design

ORIGIN: Composite Outcomes and Their Components

Glucose-Lowering Drugs and CV Outcomes

EXAMINE: Study Design

EXAMINE: Primary Endpoint

EXAMINE: CV Death

TECOS: Study Design

TECOS: Effect of Sitagliptin vs Placebo on the Primary CV Outcome

TECOS: Effect of Sitagliptin vs Placebo on the Secondary CV Outcome

SAVOR-TIMI 53: Study Design

SAVOR-TIMI 53: Effect of Saxagliptin vs Placebo on the Primary CV Outcome

SAVOR-TIMI 53: Effect of Saxagliptin vs Placebo on the Secondary CV Outcome

ELIXA: Study Design

ELIXA: Effect of Lixisenatide vs Placebo on the Primary CV Outcome

ELIXA: HF Hospitalization

EMPA-REG OUTCOME: Study Design

EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on the Primary Composite Outcome

EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on Individual CV Endpoints

EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on CV Death

EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on HF Hospitalization

EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on All-Cause Mortality

Explaining the EMPA-REG OUTCOME Findings

Explaining the EMPA-REG OUTCOME Findings (cont)

Ongoing CV Outcomes Trials in T2DM

Summary

Summary (cont)

Abbreviations

Abbreviations (cont)

Abbreviations (cont)